Merck Publishes Science Paper on Scalable Oral PCSK9 Inhibitor Manufacturing
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
SANTA CRUZ, Calif., March 16, 2026 Unnatural Products has announced the successful closing of a $45 million Series B...
KANAGAWA, Japan, Dec. 17, 2025 — PeptiDream Inc. announced promising pre-clinical results for a novel oral dual IL-17A and...
